Skip to main content

Advertisement

Table 4 Results of the base-case and one-way sensitivity analyses (24 weeks)

From: Cost-utility of ferric carboxymaltose (Ferinject®) for iron-deficiency anemia patients with chronic heart failure in South Korea

Variables Input values Incremental costs (US $) Incremental QALYs ICER (US $ per QALY gained)
Base case   466 0.0210 22,192 (₩25,010,451/QALY)
Cost ratio from Berry 2001 [27]   483 0.0210 23,013
  NYHA class I 0.049    
  NYHA class II 0.049    
  NYHA class III 0.120    
  NYHA class IV 0.831    
Utilities from the mean of 2 studies based on advanced CHF patients [23, 24] 466 0.0224 20,805
  NYHA class I 0.97    
  NYHA class II 0.8    
  NYHA class III 0.63    
  NYHA class IV 0.37    
Utilities from the mean of 3 principal utility studies [2224] 466 0.0239 19,508
  NYHA class I 0.95    
  NYHA class II 0.79    
  NYHA class III 0.60    
  NYHA class IV 0.36    
FCM price ±15% (US $) 136-184 370-562 0.0210 17,630-26,754
Total number of FCM vials ± 1 vial 3-5 306-626 0.0210 14,588-29,796
CHF medical cost ± 25% US$1,185–1,975    20,028-24,356
Utilities according to NYHA class (± 10%)
  NYHA class I: ± 10% 0.84-1    20,485-24,954*
  NYHA class II: ± 10% 0.70-0.86    17,797-29,469*
  NYHA class III: ± 10% 0.55-0.67    17,945-29,073
  NYHA class IV: ± 10% 0.40-0.48    21,737-22,667
Effect-onset time sixth day 466 0.0204 22,873
Baseline CHF patient distribution from the expert survey   191 0.0547 3,496
  NYHA class II 58.3%    
  NYHA class III 41.7%    
  1. (US $1 = Kor ₩1,127).
  2. CHF, chronic heart failure; FMC, ferric carboxymaltose; ICER, incremental cost-effectiveness ratio; NYHA, New York Heart Association.
  3. The mean of 2 results from the study of Kirsch and McGuire (2000) [21] was used.
  4. A value of 1 was applied instead of 1.023 because utility weight cannot be more than 1, although the utility weight was 1.023 in NYHA class ± 10%.
  5. As the CHF medical cost increased, the ICER decreased.
  6. *As the utility weight increased, the ICER decreased.